NASDAQ:PHAS - PhaseBio Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$6.75 +0.51 (+8.17 %)
(As of 03/22/2019 04:00 PM ET)
Previous Close$6.24
Today's Range$6.12 - $6.80
52-Week Range$2.55 - $8.88
Volume186,600 shs
Average Volume174,345 shs
Market Capitalization$165.36 million
P/E RatioN/A
Dividend YieldN/A
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase 1 clinical trial and is been developed for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery. It is also developing PB1046, a fusion protein currently in a Phase 2b clinical trial for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is based in Malvern, Pennsylvania.

Receive PHAS News and Ratings via Email

Sign-up to receive the latest news and ratings for PHAS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:PHAS



Sales & Book Value

Annual SalesN/A



Market Cap$165.36 million
Next Earnings Date3/26/2019 (Confirmed)
OptionableNot Optionable

PhaseBio Pharmaceuticals (NASDAQ:PHAS) Frequently Asked Questions

What is PhaseBio Pharmaceuticals' stock symbol?

PhaseBio Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHAS."

How were PhaseBio Pharmaceuticals' earnings last quarter?

PhaseBio Pharmaceuticals Inc (NASDAQ:PHAS) announced its quarterly earnings data on Thursday, November, 29th. The company reported ($10.45) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $10.23. The company earned $0.41 million during the quarter. View PhaseBio Pharmaceuticals' Earnings History.

When is PhaseBio Pharmaceuticals' next earnings date?

PhaseBio Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March 26th 2019. View Earnings Estimates for PhaseBio Pharmaceuticals.

What price target have analysts set for PHAS?

4 Wall Street analysts have issued twelve-month target prices for PhaseBio Pharmaceuticals' stock. Their forecasts range from $14.00 to $18.00. On average, they anticipate PhaseBio Pharmaceuticals' share price to reach $16.6667 in the next twelve months. This suggests a possible upside of 146.9% from the stock's current price. View Analyst Price Targets for PhaseBio Pharmaceuticals.

What is the consensus analysts' recommendation for PhaseBio Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PhaseBio Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for PhaseBio Pharmaceuticals.

Has PhaseBio Pharmaceuticals been receiving favorable news coverage?

News stories about PHAS stock have been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. PhaseBio Pharmaceuticals earned a news impact score of 1.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future.

Who are some of PhaseBio Pharmaceuticals' key competitors?

What other stocks do shareholders of PhaseBio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PhaseBio Pharmaceuticals investors own include Aurora Cannabis (ACB), Alibaba Group (BABA), Micron Technology (MU), Philip Morris International (PM), AcelRx Pharmaceuticals (ACRX), Gulfport Energy (GPOR), AbbVie (ABBV), Cronos Group (CRON), vTv Therapeutics (VTVT) and Rigel Pharmaceuticals (RIGL).

Who are PhaseBio Pharmaceuticals' key executives?

PhaseBio Pharmaceuticals' management team includes the folowing people:
  • Mr. Jonathan P. Mow, CEO & Director (Age 54)
  • Mr. John P. Sharp, Chief Financial Officer (Age 54)
  • Dr. John S. Lee, Chief Medical Officer (Age 51)
  • Mr. Clay Bernardin Thorp, Chairman (Age 51)
  • Mr. Michael B. York, VP of Corp. Devel. & Commercial Strategy (Age 54)

When did PhaseBio Pharmaceuticals IPO?

(PHAS) raised $66 million in an initial public offering on Thursday, October 18th 2018. The company issued 5,000,000 shares at $12.50-$14.00 per share. Citigroup, Cowen and Stifel acted as the underwriters for the IPO and Needham was co-manager.

When does PhaseBio Pharmaceuticals' lock-up period expire?

PhaseBio Pharmaceuticals' lock-up period expires on Tuesday, April 16th. PhaseBio Pharmaceuticals had issued 9,200,000 shares in its public offering on October 18th. The total size of the offering was $46,000,000 based on an initial share price of $5.00. After the end of PhaseBio Pharmaceuticals' lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

Who are PhaseBio Pharmaceuticals' major shareholders?

PhaseBio Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (0.54%), Citigroup Inc. (0.46%), United Services Automobile Association (0.38%) and BlackRock Inc. (0.10%). Company insiders that own PhaseBio Pharmaceuticals stock include Clay Thorp, John P Sharp, Jonathan P Mow, Linda Tufts, Michael York, Nancy J Hutson and Venture Advisors Iii Hatteras. View Institutional Ownership Trends for PhaseBio Pharmaceuticals.

Which institutional investors are buying PhaseBio Pharmaceuticals stock?

PHAS stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Citigroup Inc., United Services Automobile Association and BlackRock Inc.. Company insiders that have bought PhaseBio Pharmaceuticals stock in the last two years include Clay Thorp, John P Sharp, Jonathan P Mow, Linda Tufts, Michael York, Nancy J Hutson and Venture Advisors Iii Hatteras. View Insider Buying and Selling for PhaseBio Pharmaceuticals.

How do I buy shares of PhaseBio Pharmaceuticals?

Shares of PHAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is PhaseBio Pharmaceuticals' stock price today?

One share of PHAS stock can currently be purchased for approximately $6.75.

How big of a company is PhaseBio Pharmaceuticals?

PhaseBio Pharmaceuticals has a market capitalization of $165.36 million.

What is PhaseBio Pharmaceuticals' official website?

The official website for PhaseBio Pharmaceuticals is

How can I contact PhaseBio Pharmaceuticals?

PhaseBio Pharmaceuticals' mailing address is 1 Great Valley Parkway Suite 30, Malvern PA, 19355. The company can be reached via phone at 610-981-6500 or via email at [email protected]

MarketBeat Community Rating for PhaseBio Pharmaceuticals (NASDAQ PHAS)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  46 (Vote Outperform)
Underperform Votes:  52 (Vote Underperform)
Total Votes:  98
MarketBeat's community ratings are surveys of what our community members think about PhaseBio Pharmaceuticals and other stocks. Vote "Outperform" if you believe PHAS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PHAS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/22/2019 by Staff

Featured Article: Return on Equity (ROE)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel